1. Home
  2. ORIO vs LPCN Comparison

ORIO vs LPCN Comparison

Compare ORIO & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ORIO

Orion Digital Corp. Common Shares

N/A

Current Price

$0.85

Market Cap

23.0M

Sector

N/A

ML Signal

N/A

Logo Lipocine Inc.

LPCN

Lipocine Inc.

HOLD

Current Price

$2.56

Market Cap

19.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ORIO
LPCN
Founded
N/A
1997
Country
Canada
United States
Employees
188
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.0M
19.1M
IPO Year
N/A
2011

Fundamental Metrics

Financial Performance
Metric
ORIO
LPCN
Price
$0.85
$2.56
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
33.2K
103.2K
Earning Date
03-12-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
46.18
EPS
N/A
N/A
Revenue
N/A
$1,976,677.00
Revenue This Year
$74.52
N/A
Revenue Next Year
$5.07
$92.00
P/E Ratio
$4.93
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.81
$1.81
52 Week High
$1.40
$12.37

Technical Indicators

Market Signals
Indicator
ORIO
LPCN
Relative Strength Index (RSI) 41.16 60.16
Support Level $0.84 $2.59
Resistance Level $0.98 $2.67
Average True Range (ATR) 0.06 0.19
MACD 0.00 0.06
Stochastic Oscillator 25.51 89.30

Price Performance

Historical Comparison
ORIO
LPCN

About ORIO Orion Digital Corp. Common Shares

Orion Digital Corp is a financial technology company operating digital platforms across wealth and payments, supported by a consumer lending business in Canada. The Company's Wealth platform, Intelligent Investing, provides long-term investment solutions to the Canadian market. It also operates a consumer lending business in Canada. Its Payments business is conducted through its wholly owned subsidiary, which provides issuer processing, program management, and regulated payment orchestration services across Europe. The Company operates in Canada and Europe, with Canada generating the majority of its revenue.

About LPCN Lipocine Inc.

Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.

Share on Social Networks: